SDC1 and Miyoshi myopathy: The introduction of anti-CD138 monoclonal antibodies in the treatment of MM and, more recently, amyloidosis [34,35], both in the first line and in the relapsed/refractory setting, represents a viable tool for achieving rapid plasma cell clearance and preventing further amyloid deposition in tissues which may be responsible for FVII sequestration.